Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Relapsed/Refractory Leukemias

NCT01239108 · clinicaltrials.gov ↗
PHASE1
Phase
WITHDRAWN
Status
INDUSTRY
Sponsor class

Stopped The dose limiting toxicity of cardiac QTc prolongation was identified and demonstrated unsafe to continue clinical development of this molecule.

Conditions

Interventions

Sponsor

Astex Pharmaceuticals, Inc.